Neuroimmune endocrine effects of antidepressants

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 65-83

  Antonioli, Marco ^a   Rybka, Joanna ^a   Carvalho, Livia A ^a  

^a UNIVERSITY OF ROEHAMPTON   (United Kingdom)

Author keywords

Antidepressant agents; Biological markers; Cytokines; Endophenotype; Human; Neuroinflammation; Psychoneuroimmunology

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BETA INTERFERON; CLOMIPRAMINE; CLORGYLINE; CORTICOTROPIN; CYTOKINE; DESIPRAMINE; DEXAMETHASONE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID RECEPTOR; IMIPRAMINE; INTERLEUKIN 1; INTERLEUKIN 6; MAPROTILINE; MELATONIN; MIRTAZAPINE; MITOGEN ACTIVATED PROTEIN KINASE; NORADRENALIN; PAROXETINE; PIRLINDOLE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THYROTROPIN; TRANYLCYPROMINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VENLAFAXINE;

CIRCADIAN RHYTHM; DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; HAMILTON SCALE; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; NEUROENDOCRINE SYSTEM; PINEALOCYTE; REVIEW; TREATMENT RESPONSE;

EID: 84857086280     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S16409     Document Type: Review

References (210)

1. Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003;74(1):5-13.
2. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol. 2004;19(6):397-403.
3. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23(7):571-585.
4. Carvalho LA, Pariante CM. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress. 2008;11(6):411-424.
5. Lee S, Jeong J, Kwak Y, Park SK. Depression research: where are we now? Mol Brain. 2010;3:8.
6. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):722-779.
7. Anacker C, Zunszain PA, Carvalho LA, Pariante CM. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology. 2011;36(3):415-425.
8. Axelrod J, Wurtman RJ, Snyder SH. Control of hydroxyindole O-methyltransferase activity in the rat pineal gland by environmental lighting. J Biol Chem. 1965;240:949-954.
9. Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors. 2009;35(2):183-192.
10. Maronde E, Stehle JH. The mammalian pineal gland: known facts, unknown facets. Trends Endocrinol Metab. 2007;18(4):142-149.
11. Hankins MW, Lucas RJ. The primary visual pathway in humans is regulated according to long-term light exposure through the action of a nonclassical photopigment. Curr Biol. 2002;12(3):191-198.
12. Brainard GC, Sliney D, Hanifin JP, et al. Sensitivity of the human circadian system to short-wavelength (420-nm) light. J Biol Rhythms. 2008;23(5):379-386.
13. Jasser SA, Blask DE, Brainard GC. Light during darkness and cancer: relationships in circadian photoreception and tumor biology. Cancer Causes Control. 2006;17(4):515-523.
14. Deurveilher S, Semba K. Indirect projections from the suprachiasmatic nucleus to major arousal-promoting cell groups in rat: implications for the circadian control of behavioural state. Neuroscience. 2005;130(1):165-183.
15. Leander P, Vrang N, Moller M. Neuronal projections from the mesencephalic raphe nuclear complex to the suprachiasmatic nucleus and the deep pineal gland of the golden hamster (Mesocricetus auratus). J Comp Neurol. 1998;399(1):73-93.
16. Ying SW, Rusak B. Effects of serotonergic agonists on firing rates of photically responsive cells in the hamster suprachiasmatic nucleus. Brain Res. 1994;651(1-2):37-46.
17. Quintero JE, McMahon DG. Serotonin modulates glutamate responses in isolated suprachiasmatic nucleus neurons. J Neurophysiol. 1999;82(2):533-539.
18. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res. 2010;181:127-151.
19. Cowen PJ, Green AR, Grahame-Smith DG, Braddock LE. Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission. Br J Clin Pharmacol. 1985;19(6):799-805.
20. Palazidou E, Papadopoulos A, Ratcliff H, Dawling S, Checkley SA. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol Med. 1992;22(2):309-315.
21. Sugden D. Comparison of circadian expression of tryptophan hydroxylase isoform mRNAs in the rat pineal gland using real-time PCR. J Neurochem. 2003;86(5):1308-1311.
22. Agez L, Laurent V, Guerrero HY, Pevet P, Masson-Pevet M, Gauer F. Endogenous melatonin provides an effective circadian message to both the suprachiasmatic nuclei and the pars tuberalis of the rat. J Pineal Res. 2009;46(1):95-105.
23. Sotthibundhu A, Phansuwan-Pujito P, Govitrapong P. Melatonin increases proliferation of cultured neural stem cells obtained from adult mouse subventricular zone. J Pineal Res. 2010;49(3):291-300.
24. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation. 2008;15(2):93-101.
25. Maldonado MD, Murillo-Cabezas F, Calvo JR, et al. Melatonin as pharmacologic support in burn patients: a proposed solution to thermal injury-related lymphocytopenia and oxidative damage. Crit Care Med. 2007;35(4):1177-1185.
26. Maldonado MD, Murillo-Cabezas F, Terron MP, et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res. 2007;42(1):1-11.
27. Cernysiov V, Gerasimcik N, Mauricas M, Girkontaite I. Regulation of T-cell-independent and T-cell-dependent antibody production by circadian rhythm and melatonin. Int Immunol. 2010;22(1):25-34.
28. Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernandez-Vazquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res. July 26, 2011. [Epub ahead of print.]
29. Sanchez-Hidalgo M, Lu Z, Tan DX, Maldonado MD, Reiter RJ, Gregerman RI. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol. 2007;292(6):R2208-R2215.
30. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood). 2005;230(2):104-117.
31. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42(1):28-42.
32. Garcia-Navarro A, Gonzalez-Puga C, Escames G, et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res. 2007;43(2):195-205.
33. Parry BL, Meliska CJ, Sorenson DL, et al. Plasma melatonin circadian rhythm disturbances during pregnancy and postpartum in depressed women and women with personal or family histories of depression. Am J Psychiatry. 2008;165(12):1551-1558.
34. Beck-Friis J, Kjellman BF, Aperia B, et al. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand. 1985;71(4):319-330.
35. Paparrigopoulos T. Melatonin response to atenolol administration in depression: indication of beta-adrenoceptor dysfunction in a subtype of depression. Acta Psychiatr Scand. 2002;106(6):440-445.
36. Beck-Friis J, Ljunggren JG, Thoren M, von RD, Kjellman BF, Wetterberg L. Melatonin, cortisol and ACTH in patients with major depressive disorder and healthy humans with special reference to the outcome of the dexamethasone suppression test. Psychoneuroendocrinology. 1985;10(2):173-186.
37. Parry BL, Meliska CJ, Sorenson DL, et al. Increased melatonin and delayed offset in menopausal depression: role of years past menopause, follicle-stimulating hormone, sleep end time, and body mass index. J Clin Endocrinol Metab. 2008;93(1):54-60.
38. Brown R, Kocsis JH, Caroff S, et al. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J Psychiatry. 1985;142(7):811-816.
39. Fountoulakis KN, Karamouzis M, Iacovides A, et al. Morning and evening plasma melatonin and dexamethasone suppression test in patients with nonseasonal major depressive disorder from northern Greece (latitude 40-41.5 degrees). Neuropsychobiology. 2001;44(3):113-117.
40. Tuunainen A, Kripke DF, Elliott JA, et al. Depression and endogenous melatonin in postmenopausal women. J Affect Disord. 2002;69(1-3):149-158.
41. Detanico BC, Piato AL, Freitas JJ, et al. Antidepressant-like effects of melatonin in the mouse chronic mild stress model. Eur J Pharmacol. 2009;607(1-3):121-125.
42. Weil ZM, Hotchkiss AK, Gatien ML, Pieke-Dahl S, Nelson RJ. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull. 2006;68(6):425-429.
43. Wu YH, Zhou JN, Balesar R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp Neurol. 2006;499(6):897-910.
44. Rosenwasser AM. Functional neuroanatomy of sleep and circadian rhythms. Brain Res Rev. 2009;61(2):281-306.
45. Galecki P, Szemraj J, Bartosz G, et al. Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J Pineal Res. 2010;48(4):311-317.
46. Boyce P, Barriball E. Circadian rhythms and depression. Aust Fam Physician. 2010;39(5):307-310.
47. Lam RW, Levitan RD. Pathophysiology of seasonal affective disorder: a review. J Psychiatry Neurosci. 2000;25(5):469-480.
48. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656-662.
49. Okamura H. Suprachiasmatic nucleus clock time in the mammalian circadian system. Cold Spring Harb Symp Quant Biol. 2007;72:551-556.
50. Pilorz V, Steinlechner S, Oster H. Age and oestrus cycle-related changes in glucocorticoid excretion and wheel-running activity in female mice carrying mutations in the circadian clock genes Per1 and Per2. Physiol Behav. 2009;96(1):57-63.
51. Linkowski P, Van Cauter E, Leclercq R, et al. ACTH, cortisol and growth hormone 24-hour profiles in major depressive illness. Acta Psychiatr Belg. 1985;85(5):615-623.
52. Souetre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res. 1989;28(3):263-278.
53. Campino C, Valenzuela FJ, Torres-Farfan C, et al. Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. Horm Metab Res. 2011;43(5):337-342.
54. Emens J, Lewy A, Kinzie JM, Arntz D, Rough J. Circadian misalignment in major depressive disorder. Psychiatry Res. 2009;168(3):259-261.
55. Hasler BP, Buysse DJ, Kupfer DJ, Germain A. Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity: further evidence for circadian misalignment in non-seasonal depression. Psychiatry Res. 2010;178(1):205-207.
56. Buckley TM, Schatzberg AF. A pilot study of the phase angle between cortisol and melatonin in major depression-a potential biomarker? J Psychiatr Res. 2010;44(2):69-74.
57. Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress. 2004;7(4):209-219.
58. Herbert J, Goodyer IM, Grossman AB, et al. Do corticosteroids damage the brain? J Neuroendocrinol. 2006;18(6):393-411.
59. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19(3):269-301.
60. Tasker JG, Di S, Malcher-Lopes R. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology. 2006;147(12):5549-5556.
61. de Kloet ER, Derijk RH, Meijer OC. Therapy insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat Clin Pract Endocrinol Metab. 2007;3(2):168-179.
62. Navarra P, Tsagarakis S, Faria MS, Rees LH, Besser GM, Grossman AB. Interleukins-1 and-6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology. 1991;128(1):37-44.
63. Karalis K, Muglia LJ, Bae D, Hilderbrand H, Majzoub JA. CRH and the immune system. J Neuroimmunol. 1997;72(2):131-136.
64. Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology. 1993;133(6):2523-2530.
65. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23(5):477-501.
66. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry. 2000;177:390-395.
67. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/ CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res. 1994;28(4):341-356.
68. Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry. 1996;1(4):336-342.
69. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001;49(5):391-404.
70. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med. 1988;319(6):348-353.
71. Carroll BJ, Feinberg M, Greden JF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry. 1981;38(1):15-22.
72. Axelson DA, Doraiswamy PM, Boyko OB, et al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res. 1992;44(1):63-70.
73. Rubin R, Dinan TJ, Scott LV. The neuroendocrinology of affective disorders. In: Pfaff D, Arnold AP, Etgen AM, Fahrbach SE, Moss PL, Rubin RT, editors. Hormones, Brain and Behaviour. New York, NY: New York Academic Press; 2001.
74. Kunugi H, Ida I, Owashi T, Kimura M, et al. Assessment of the dexamethasone/ CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology. 2006;31(1):212-220.
75. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry. 1991;48(8):693-699.
76. Cooney JM, Dinan TG. Preservation of hypothalamic-pituitary-adrenal axis fast-feedback responses in depression. Acta Psychiatr Scand. 1996;94(6):449-453.
77. Linkowski P, Mendlewicz J, Kerkhofs M, et al. 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocrinol Metab. 1987;65(1):141-152.
78. Heuser IJ, Schweiger U, Gotthardt U, et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry. 1996;153(1):93-99.
79. Bhagwagar Z, Hafizi S, Cowen PJ. Increase in concentration of waking salivary cortisol in recovered patients with depression. Am J Psychiatry. 2003;160(10):1890-1891.
80. Tuomisto J, Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 1985;37(3):249-332.
81. Plotsky PM, Cunningham ET Jr, Widmaier EP. Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev. 1989;10(4):437-458.
82. Wurtman RJ, Altschule M, Holmgren U. Effects of pinealectomy and of a bovine pineal extract in rats. Am J Physiol. 1959;197(1):108-110.
83. Konakchieva R, Mitev Y, Almeida OF, Patchev VK. Chronic melatonin treatment and the hypothalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release. Biol Cell. 1997;89(9):587-596.
84. Konakchieva R, Mitev Y, Almeida OF, Patchev VK. Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. Neuroendocrinology. 1998;67(3):171-180.
85. Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E. Antidepressant action of agomelatine (S20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):908-916.
86. Presman DM, Hoijman E, Ceballos NR, Galigniana MD, Pecci A. Melatonin inhibits glucocorticoid receptor nuclear translocation in mouse thymocytes. Endocrinology. 2006;147(11):5452-5459.
87. Fernandes PA, Bothorel B, Clesse D, et al. Local corticosterone infusion enhances nocturnal pineal melatonin production in vivo. J Neuroendocrinol. 2009;21(2):90-97.
88. Couto-Moraes R, Palermo-Neto J, Markus RP. The immune-pineal axis: stress as a modulator of pineal gland function. Ann N Y Acad Sci. 2009;1153:193-202.
89. Ferreira ZS, Fernandes PA, Duma D, Assreuy J, Avellar MC, Markus RP. Corticosterone modulates noradrenaline-induced melatonin synthesis through inhibition of nuclear factor kappa B. J Pineal Res. 2005;38(3):182-188.
90. Fischer S, Smolnik R, Herms M, Born J, Fehm HL. Melatonin acutely improves the neuroendocrine architecture of sleep in blind individuals. J Clin Endocrinol Metab. 2003;88(11):5315-5320.
91. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214-217.
92. Jehn CF, Kuhnhardt D, Bartholomae A, et al. Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther. 2010;9(3):270-275.
93. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab. 2005;90(5):2522-2530.
94. Bouhuys AL, Flentge F, Oldehinkel AJ, van den Berg MD. Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Res. 2004;127(3):237-245.
95. Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MM. Inflammatory proteins and depression in the elderly. Epidemiology. 2003;14(1):103-107.
96. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370-379.
97. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol. 2001;11(3):203-208.
98. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003;170(4):429-433.
99. Owen BM, Eccleston D, Ferrier IN, Young AH. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand. 2001;103(3):226-228.
100. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164(9):1010-1014.
101. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65(3):347-356.
102. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT. Increase in interleukin-1beta in late-life depression. Am J Psychiatry. 2005;162(1):175-177.
103. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology. 2003;28(6):1182-1185.
104. Jun TY, Pae CU, Hoon H, et al. Possible association between G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet. 2003;13(3):179-181.
105. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56(11):819-824.
106. Pariante CM, Pearce BD, Pisell TL, et al. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology. 1999;140(9):4359-4366.
107. Orru MG, Baita A, Sitzia R, et al. Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: a prospective, observational, controlled study. Epidemiol Psichiatr Soc. 2005;14(3):145-153. Italian.
108. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
109. Huang Y, Henry CJ, Dantzer R, Johnson RW, Godbout JP. Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiol Aging. 2008;29(11):1744-1753.
110. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21(1):9-19.
111. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuroimmune-endocrine interactions: a role for the hypothalamic-pituitaryadrenal revolving axis. J Neuroimmunol. 2002;133(1-2):1-19.
112. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 1998;83(5):1573-1579.
113. Maddock C, Pariante CM. How does stress affect you? An overview of stress, immunity, depression and disease. Epidemiol Psichiatr Soc. 2001;10(3):153-162. Italian.
114. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH. Steroidindependent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol. 1997;52(4):571-581.
115. Wang X, Wu H, Miller AH. Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol Psychiatry. 2004;9(1):65-75.
116. Pierpaoli W. Neuroimmunomodulation of aging. A program in the pineal gland. Ann N Y Acad Sci. 1998;840:491-497.
117. Skwarlo-Sonta K, Majewski P, Markowska M, Oblap R, Olszanska B. Bidirectional communication between the pineal gland and the immune system. Can J Physiol Pharmacol. 2003;81(4):342-349.
118. da Silveira Cruz-Machado S, Carvalho-Sousa CE, Tamura EK, et al. TLR4 and CD14 receptors expressed in rat pineal gland trigger NFKB pathway. J Pineal Res. 2010;49(2):183-192.
119. Branchey L, Weinberg U, Branchey M, Linkowski P, Mendlewicz J. Simultaneous study of 24-hour patterns of melatonin and cortisol secretion in depressed patients. Neuropsychobiology. 1982;8(5):225-232.
120. Blomeke B, Golka K, Griefahn B, Roemer HC. Arylalkylamine N-acetyltransferase (AANAT) genotype as a personal trait in melatonin synthesis. J Toxicol Environ Health A. 2008;71(13-14):874-876.
121. Cardinali DP, Vacas MI, Keller Sarmiento MI, Etchegoyen GS, Pereyra EN, Chuluyan HE. Neuroendocrine integrative mechanisms in mammalian pineal gland: effects of steroid and adenohypophyseal hormones on melatonin synthesis in vitro. J Steroid Biochem. 1987;27(1-3):565-571.
122. Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation. 2000;101(20):2338-2341.
123. Schauenstein K, Felsner P, Rinner I, et al. In vivo immunomodulation by peripheral adrenergic and cholinergic agonists/antagonists in rat and mouse models. Ann N Y Acad Sci. 2000;917:618-627.
124. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103(2):182-186.
125. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. 2003;100(4):1920-1925.
126. Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol. 1986;13(1):19-30.
127. Chuang JI, Mohan N, Meltz ML, Reiter RJ. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int. 1996;20(10):687-692.
128. Mohan N, Sadeghi K, Reiter RJ, Meltz ML. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int. 1995;37(6):1063-1070.
129. Cristofanon S, Uguccioni F, Cerella C, et al. Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kappaB activation. Ann N Y Acad Sci. 2009;1171:472-478.
130. Cecon E, Fernandes PA, Pinato L, Ferreira ZS, Markus RP. Daily variation of constitutively activated nuclear factor kappa B (NFKB) in rat pineal gland. Chronobiol Int. 2010;27(1):52-67.
131. Jin W, Wang H, Yan W, et al. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediators Inflamm. 2008;2008:725174.
132. Thimmulappa RK, Lee H, Rangasamy T, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 2006;116(4):984-995.
133. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004;125(10-11):697-706.
134. Miller MA, Kandala NB, Kivimaki M, et al. Gender differences in the cross-sectional relationships between sleep duration and markers of inflammation: Whitehall II study. Sleep. 2009;32(7):857-864.
135. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27(2):189-200.
136. Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol. 2010;80(12):1844-1852.
137. Skwarlo-Sonta K. Melatonin in immunity: comparative aspects. Neuro Endocrinol Lett. 2002;23 Suppl 1:61-66.
138. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004;29(1):11-17.
139. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538-544.
140. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12(11):988-1000.
141. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory and neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24(1):27-53.
142. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14(5):511-522.
143. Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol. 2010;25(3):117-131.
144. Parfitt A, Klein DC. Increase caused by desmethylimipramine in the production of [3H]melatonin by isolated pineal glands. Biochem Pharmacol. 1977;26(9):904-905.
145. Cowen PJ, Fraser S, Grahame-Smith DG, Green AR, Stanford C. The effect of chronic antidepressant administration on beta-adrenoceptor function of the rat pineal. Br J Pharmacol. 1983;78(1):89-96.
146. Franklin M, Clement EM, Campling G, Cowen PJ. Effect of venlafaxine on pineal melatonin and noradrenaline in the male rat. J Psychopharmacol. 1998;12(4):371-374.
147. Uz T, Ahmed R, Akhisaroglu M, et al. Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. Neuroscience. 2005;134(4):1309-1316.
148. Pastrakuljic A, Tang BK, Roberts EA, Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol. 1997;53(4):531-538.
149. Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001;21(2):167-174.
150. Badawy AA, Morgan CJ. Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat. Br J Pharmacol. 1991;102(2):429-433.
151. Bearn J, Franey C, Arendt J, Checkley SA. A study of the effects of desipramine treatment alone and in combination with L-triiodothyronine on 6-sulphatoxymelatonin excretion in depressed patients. Br J Psychiatry. 1989;155:341-347.
152. Kennedy SH, Brown GM. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiatry Res. 1992;43(2):177-185.
153. Thompson C, Mezey G, Corn T, et al. The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiatry. 1985;147:389-393.
154. Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988;45(2):150-154.
155. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEXCRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31(4):832-844.
156. Carvalho L, Gorenstein C, Moreno R, Pariante C, Markus R. Effect of antidepressants on melatonin metabolite in depressed patients. J Psychopharmacol. 2009;23(3):315-321.
157. Rabe-Jablonska J, Szymanska A. Diurnal profile of melatonin secretion in the acute phase of major depression and in remission. Med Sci Monit. 2001;7(5):946-952.
158. Miller HL, Ekstrom RD, Mason GA, Lydiard RB, Golden RN. Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology. 2001;24(6):617-623.
159. Franey C, Aldhous M, Burton S, Checkley S, Arendt J. Acute treatment with desipramine stimulates melatonin and 6-sulphatoxy melatonin production in man. Br J Clin Pharmacol. 1986;22(1):73-79.
160. Demisch K, Demisch L, Bochnik HJ, et al. Melatonin and cortisol increase after fluvoxamine. Br J Clin Pharmacol. 1986;22(5):620-622.
161. Palazidou E, Skene D, Arendt J, Everitt B, Checkley SA. The acute and chronic effects of (a) and () oxaprotiline upon melatonin secretion in normal subjects. Psychol Med. 1992;22(1):61-67.
162. Palazidou E, Papadopoulos A, Sitsen A, Stahl S, Checkley S. An alpha 2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology (Berl). 1989;97(1):115-117.
163. Markus RP, Franco DG, Carvalho LA, Gentil V, Gorenstein C. Acute increase in urinary 6-sulfatoximelatonin after clomipramine, as a predictive measure for emotional improvement. J Psychopharmacol. 2010;24(6):855-860.
164. Demisch K, Demisch L, Nickelsen T, Rieth R. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm. 1987;68(3-4):257-270.
165. Skene DJ, Bojkowski CJ, Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol. 1994;37(2):181-186.
166. Celada P, Perez J, Alvarez E, Artigas F. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. J Clin Psychopharmacol. 1992;12(5):309-315.
167. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006;318(2):604-610.
168. Childs PA, Rodin I, Martin NJ, et al. Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. Br J Psychiatry. 1995;166(2):196-198.
169. Nathan PJ, Norman TR, Burrows GD. Nocturnal plasma melatonin concentrations in healthy volunteers: effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. J Pineal Res. 1996;21(2):55-58.
170. Tan ZL, Bao AM, Zhao GQ, Liu YJ, Zhou JN. Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder. Neuro Endocrinol Lett. 2007;28(1):28-32.
171. Cuesta M, Mendoza J, Clesse D, Pevet P, Challet E. Serotonergic activation potentiates light resetting of the main circadian clock and alters clock gene expression in a diurnal rodent. Exp Neurol. 2008;210(2):501-513.
172. Sprouse J, Braselton J, Reynolds L. Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. Biol Psychiatry. 2006;60(8):896-899.
173. Peiffer A, Veilleux S, Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology. 1991;16(6):505-515.
174. Pariante CM, Makoff A, Lovestone S, et al. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol. 2001;134(6):1335-1343.
175. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol. 1999;11(11):887-895.
176. Carvalho LA, Garner BA, Dew T, Fazakerley H, Pariante CM. Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. Eur Neuropsychopharmacol. 2010;20(6):379-387.
177. Hu J, Xia Y, Wu Z, Liu L, Tang C. Fluoxetine might alleviate brain damage and hypercortisolemia related to chronic alcohol in rats. J Stud Alcohol Drugs. 2010;71(2):290-294.
178. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3(2):97-106.
179. Fischli S, Jenni S, Allemann S, et al. Dehydroepiandrosterone sulfate in the assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 2008;93(2):539-542.
180. Schule C, Baghai TC, Eser D, Schwarz M, Bondy B, Rupprecht R. Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients. J Psychiatr Res. 2009;43(5):538-545.
181. Paslakis G, Luppa P, Gilles M, et al. Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosteronesulfate in depressed patients remitting during the course of treatment. J Psychiatr Res. 2010;44(8):556-560.
182. Binder EB, Kunzel HE, Nickel T, et al. HPA-axis regulation at inpatient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology. 2009;34(1):99-109.
183. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry. 2009;194(4):342-349.
184. Hallam KT, Begg DP, Olver JS, Norman TR. An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers. Hum Psychopharmacol. 2008;23(2):129-137.
185. Ahrens T, Frankhauser P, Lederbogen F, Deuschle M. Effect of singledose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous system, and platelet function. J Clin Psychopharmacol. 2007;27(6):602-606.
186. Hashioka S, Klegeris A, Monji A, et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol. 2007;206(1):33-42.
187. Obuchowicz E, Kowalski J, Labuzek K, Krysiak R, Pendzich J, Herman ZS. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int J Neuropsychopharmacol. 2006;9(1):27-35.
188. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol. 2009;12(4):525-536.
189. Taler M, Gil-Ad I, Lomnitski L, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007;17(12):774-780.
190. Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology. 1996;34(1):27-37.
191. Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, Marmurowska-Michalowska H, Kandefer-Szerszen M. In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol J Pharmacol. 2003;55(3):353-362.
192. Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999;20(4):370-379.
193. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21(2):199-206.
194. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1044-1053.
195. Sutcigil L, Oktenli C, Musabak U, et al. Pro-and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol. 2007;2007:76396.
196. Walsh HA, Daya S. Influence of the antidepressants desipramine and fluoxetine on tryptophan-2,3-dioxygenase in the presence of exogenous melatonin. Life Sci. 1998;62(26):2417-2423.
197. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol. 2010;25(3):201-215.
198. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-964.
199. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628-642.
200. Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat. 2009;5:563-576.
201. Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav. 1996;54(4):713-718.
202. Van RO, Weibel L, Olivares E, Maccari S, Mocaer E, Turek FW. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol. 2001;280(5):R1582-R1591.
203. Cajochen C, Krauchi K, Mori D, Graw P, Wirz-Justice A. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol. 1997;272(4 Pt 2): R1189-R1196.
204. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol. 1997;272(4 Pt 2): R1178-R1188.
205. Llorca PM. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. J Psychopharmacol. 2010;24(Suppl 2):21-26.
206. Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol. 2010;25(3):222-229.
207. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71(2):109-120.
208. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661-673.
209. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266.
210. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19(5):271-280.